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ABSTRACT Bruton tyrosine kinase (Btk) has been impli-
cated as the defective gene in both human and murine B-cell
deficiencies. The identfication of molecules that Interact with
Btk may shed light on critical processes In lymphocyte devel-
opment. The N-terminal unique region of Btk conas a
pleckstrln homolo domain. is domain is found in a broad
array of s ing mol and implted to in
proteiprorotein itectns. By using an in vitro bidwingay
and an in vivo competition assay, the pleckstrin homology
domain of Btk was shown to interact with the IPy dimer of
heterotrimeric gun nucleotide-binding proteins (G pro-
teins). A highly conserved tryptophan residue In subdomain 6
of thepl hlo domain was shown to play a critical
role in the bing. The interaction of Btk with Iy suggesI the
existence of a unique connection between cplasc tyrosine
kinases and G proteins in cellular signal transduction.
Deficient expression or function of Bruton tyrosine kinase
(Btk) has recently been identified as the genetic basis for
human X chromosome-linked agammaglobulinemia (XLA)
and murine X chromosome-linked immunodeficiency (XID)
(1-4). Btk contains a single catalytic domain and two well-
described protein interaction domains called SH2 and SH3.
These features are also found in a large family of cytoplasmic
tyrosine kinases closely related to the src gene. A defining
feature ofBtk structure and its close relatives Itk (5), Tsk (6),
Tec (7), and Drosophila src (Dsrc28C) (8) is the presence of
a highly basic N-terminal region ofabout 200 amino acids (aa)
in length that lacks a myristoylation signal (1).
XLA is characterized by a block in pre-B-cell differentia-
tion in the bone marrow, a generalized loss of functional B
lymphocytes, and failure of immunoglobulin production.
Patients experience serious bacterial infections that can be
life threatening. Mutations that restrict expression, inactivate
kinase activity, or alter potential protein-protein interactions
by mutation of the SH2 or SH3 domain have been defined in
different individuals (1, 2, 9-11). XID is characterized by a
mild deficiency of total B-cell numbers and a selective loss of
some immunoglobulin subclasses and B-cell subsets, lack of
response to some T-cell-independent antigens, and failure to
respond to certain cytokines, such as interleukin 5 or inter-
leukin 10, and signals delivered through cell surface struc-
tures, including immunoglobulin and CD38 (refs. 12 and 13;
M. Howard, personal communication). XID is caused by a
mutation in the N-terminal unique region of Btk, which
results in an arginine at position 28 of the wild-type enzyme
being converted to a cysteine residue. A human mutation in
a classical XLA patient has recently been defined as Arg-28
changed to histidine (10).
The N-terminal unique region of Btk contains a pleckstrin
homology (PH) domain (14) that is found in numerous sig-
naling proteins including several serine/threonine kinases,
GTPases, GTP-activating proteins, nucleotide-releasing fac-
tors, and phospholipases (15, 16). Six weakly conserved
sequence blocks define the PH domain. Within subdomain 6
a single tryptophan residue is conserved in all characterized
sequences (14). The altered arginine residue in XID andXLA
is located in subdomain 2 and is conserved in >60% of
identified PH domains.
A significant insight to the potential function of PH do-
mains comes from the demonstration that the fl-adrenergic
receptor kinase (BARK) and several phospholipases that
contain PH domains can interact with the By subunit complex
of heterotrimeric guanine nucleotide-binding proteins (G
proteins) (17-21). This type of interaction could potentially
recruit PARK or other PH domain-containing molecules to
the cell membrane (22, 23). Although Btk is found in the
cytoplasm (ref. 1; S.T. and O.N.W., unpublished data), a
small fraction relocates to the membrane fraction in mast
cells stimulated through the IgE receptor (24) that correlates
with activation of Btk kinase activity and an increase in
phosphotyrosine content. Although the overall degree of
sequence identity between the Btk and BARK PH domains is
limited (8% identical residues and 12% conserved residues,
see Fig. 1), we wished to test the possibility that the PH
domain of Btk could also mediate interaction with fBy sub-
units. Our data from in vitro binding assays and in vivo
competition experiments strongly support this conclusion
and implicate heterotrimeric G protein signaling pathways in
the regulation of a tyrosine kinase signaling pathway critical
for the development and function of B lymphocytes.
MATERIALS AND METHODS
Materials. For fusion constructs of Btk and glutathione
S-transferase (GST), fragments of the Btk N-terminal region
were generated by PCR using the cDNA of murine Btk (1) as
templates and cloned into pGEX vector (Pharmacia). Three
constructs, GST-BTK(PH) (aa 1-196), GST-BTK(PH)N (aa
1-73), and GST-BTK(PH)C (aa 94-165), of the Btk unique
region were made. GST-f3ARK contains 222 aa from the
C-terminal residue of BARK1 fused toGST (17). GST-SH3 (aa
218-263, the SH3 domain), GST-SH2 (aa 264-382, the SH2
domain), and GST-BTK(Ct) (aa 589-659, a part of the kinase
domain and its C-terminal flanking sequence) of murine Btk
cDNA were made as control constructs. GST-ABL1 (aa
1044-1149) and GST-ABL2 (aa 731-825) contain the C-termi-
nal unique region of Abl. The GST fusion proteins were
purified as described (25). For transfection experiments, the
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FIG. 1. Comparison of the PH domains of Btk and PARK1. The
PH domain is divided into six subdomains and alignment was
accomplished by the method outlined by Musacchio et al. (14). The
N-terminal unique region of Btk contains 217 aa and the PH domain
is composed of the first 137 aa. Subdomains 1 (aa 1-17), 2 (aa 18-34),
3 (aa 35-42), and 4 (aa 43-73) are adjacent to each other. There is an
insert of 20 aa between subdomains 4 and 5 (aa 94-110) and
subdomain 6 (aa 111-137) is adjacent to subdomain 5. The PH domain
ofLARK1 is composed of aa 559-652. The identical amino residues
and the conserved amino residues between Btk and 8ARK1 are
shown by black boxes and shaded boxes, respectively. The arginine
that is altered in XID (*) and the conserved tryptophan in subdomain
6 (o) are shown.
Btk fragments were generated by PCR [aa 1-1% for BTK(PH),
aa 1-123 for BTK(PH)1-123] and cloned between Cla I and
Not I sites of pCIS expression vector (26). BTK(PH)W124G
was made from two PCR fragments by introducing a BamHI
site via a silent mutation near Trp-124. The M2 acetylcholine
receptor (M2AChR) cDNA and the bacterial 3-galactosidase
gene were both inserted into pCIS. Anti-p31 antiserum was
generated against the first 14 aa of pi protein and anti--y2
antiserum was generated against the first 15 aa of y2 protein.
Anti-Btk antiserum preparation was as described (1).
In Vitro Binding of ,By and GST Fusion Proteins. 293T cells
(4 x 106 cells per 10-cm dish) were transfected with 5 Pg of
/31 and/or y2 cDNA by the calcium phosphate method. After
60-72 hr, cells were harvested, washed twice with phos-
phate-buffered saline (PBS), and lysed with lysis buffer (0.5%
lubrol in PBS, PH 7.0/1 mM phenylmethyl sulfonyl fluo-
ride/1 mM EDTA/10 pg of aprotinin per ml/10 pg of
leupeptin per ml). Cells were incubated with the lysis buffer
for 20 min on ice and centrifuged at 100,000 x g for 30 min
at 4TC. The supernatant was dialyzed against 0.01% lubrol/
PBS overnight and used as the source of 13i or y2 proteins in
subsequent experiments. In typical experiments, 5 ug ofGST
protein immobilized on glutathione S-Sepharose beads (Phar-
macia) was incubated with the cell lysate for 2 hr at 40C and
washed four times with 0.01% lubrol/PBS. SDS gel loading
buffer was added to the beads and the samples were resolved
on a 15% SDS/polyacrylamide gel and electroblotted on a
nitrocellulose filter (0.45-,um pore size filter for Pi blotting,
0.2-,um pore size filter for y2 blotting) (Schleicher & Schuell).
The blots were probed with anti-P, or anti-y2 antiserum and
processed using the enhanced chemiluminescence detection
system (Amersham).
Inhibition Experiments of PrMediated Phospholipase C p
Isoform Activation by Btk Constructs. COS-7 cells (1 x 105
cells per well) were seeded in 12-well plates 1 day before
transfection. The total amount of DNA in all transfections
was 0.9 pg per well. Nine-tenth microgram of DNA mixed
with 5 jAd of LipofectAmine (Bethesda Research Laborato-
ries) in 0.5 ml of Opti-MEM (Bethesda Research Laborato-
ries) was added to each well and 5 hr later 0.5 ml of 20% fetal
calf serum (FCS) in Dulbecco's modified Eagle medium
(DMEM) was added. One day posttransfection, the medium
was removed and the cells were washed with PBS and
incubated in 0.4 ml of inositol-free DMEM with 10%o dialyzed
FCS containing 10 ,uCi of myo-[2-3H]inositol per ml (NEN; 1
Ci = 37 GBq). Twenty-four hours later, the cells were washed
with PBS and 200 1.d of inositol-free medium containing 10
mM LiCl was added. The cells were incubated for 10 min at
370C and then incubated with 100 AM carbachol for 25 min at
370C (baselines were obtained without carbachol). Each
reaction was stopped by adding 200 14 of cold 10%6 perchloric
acid and 20 ,ul of phytic acid (20 mg/ml) and incubated on ice
for 10 min. Then 200 Al of the supernatant was transferred to
a microcentrifuge tube and neutralized with 2 M KOH. After
centrifugation, the supernatant was loaded on a 0.5-ml
AG1-X8 anion-exchange column (200-400 mesh, formate
form, Bio-Rad). The separation was done as described (27),
0.5 ml of the elution was mixed with 10 ml of scintillation
cocktail BCS (Amersham), and 3H-labeled inositol phosphate
[3H]IP levels were counted.
RESULTS
In Vitro Binding of the Btk PH Domain to the Py Dimer of
Heterotrimeric G Proteins. We utilized an immobilized ligand
strategy similar to that employed by Koch et al. (20) in their
analysis of the interaction of the PH domain of PARK to fry
dimers. GST fusion constructs of the entire PH domain of
,BARK and Btk, as well as an N-terminal fragment (residues
1-73) and a C-terminal fragment (residues 94-165) of the Btk
PH domain were prepared (Fig. 2A and Materials and
Methods). The N-terminal fragment contained subdomains
1-4 of the PH domain, while the C-terminal region contained
subdomains 5 and 6. Each fusion protein was expressed in
bacteria and used following extraction and affinity chroma-
tography on glutathione S-Sepharose. Preparations were
prechecked for amount of expression of the desired protein
and intactness prior to use.
13i, y2, or a combination of both proteins was prepared by
transfection of 293T cells as described (Materials and Meth-
ods). Total cell extracts were prepared and analyzed for
binding to control beads containing GST alone, the GST-
,ARK(PH) fusion protein, or the GST-BTK(PH) fusion
protein (Fig. 2B). Following extensive washing, bound pro-
teins were released by boiling in SDS-containing buffer,
separated by gel electrophoresis, transferred to nitrocellulose
membranes, and analyzed by immunoblotting with either
Pi-specific or y2-specific antibodies. Both GST-3ARK(PH)
and GST-BTK(PH) could efficiently bind a complex of (1'y2
but neither could bind the singly expressed P1 or y2 forms. A
small amount of P, recovered in the single transfection
protocol could represent complexing with endogenous y
proteins in 293T cells. The specificity of these interactions
was further tested by evaluating a panel of additional GST
fusions with protein fragments including the Btk SH2, SH3
domains and several irrelevant protein fragments derived
from the c-Abl oncogene. No detectable binding to Pi, Y2, or
a combination of 1j31y2 was observed (data not shown).
To further detail the relative efficiency of binding of (3Y2
to the Btk and PARK PH domains, a dilution series to vary
the amount of each GST fusion protein was compared (Fig.
2C, top panel). To maintain a constant amount oftotal protein
on the beads for each reaction, an amount ofGST protein was
added to compensate for dilution of the specific PH domain
fusions. Extracts from 293T cells coexpressing ,1 and y2 were
tested as described above. Immunoblotting to detect the
amount of j31 or -Y2bound shows that the interaction ofthe PH
domain of Btk with 813y2 is as strong as the PH domain of
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FIG. 2. Detection of binding of fBy to GST fusion proteins in vitro. (A) PH domain constructs used in in vitro binding assay. GST-(3ARK(PH)
contains 222 aa of the C-terminal region of.3ARK1. GST-BTK(PH) contains all ofthe PH domain and its C-terminal flanking sequence (aa 1-196).
GST-BTK(PH)N contains subdomains 1-4 and GST-BTK(PH)C contains subdomains 5, 6, and its C-terminal flanking sequence. (B) Five
micrograms of GST, GST-,3ARK, or GST-BTK(PH) immobilized on glutathione S-Sepharose beads was incubated with (31 protein, )2 protein,
or a mixture of P1i and -y2 proteins. After incubation, beads were washed and 81 or 'y protein bound on beads was detected by anti-(3s or anti-yz
blot (see text). (C) Comparison of the binding affinities of GST-BTK(PH) and GST-/3ARK(PH) to (3y. The amounts of fusion proteins were
sequentially decreased while the total amounts of GST proteins were kept constant at 5 jug with neat GST. GST proteins were incubated with
a mixture of (31 and y2, and the binding affinities were compared. (D) Binding affinities of truncated PH domain constructs to PiW.
BARK under these conditions (Fig. 2C, middle and bottom
panels).
The family of proteins containing PH domains is quite
diverse and various signaling pathways could be affected by
PH domain interactions. There is no reason to assume that
the sequence homology region defined as the PH domain
would only mediate a single type of protein-protein interac-
tion. The SH2 domain, which is about 100 aa in length, can
mediate both phosphotyrosine-dependent and phospho-
serine-dependent interactions with different proteins (28, 29).
The PH domain in Btk is organized with subdomains 1-4 over
the first 73 residues, followed by a region of no homology of
21 residues and then subdomains 5 and 6 in a run of 43
residues. We wished to test if the interaction with fry dimers
required the entire Btk PH region or could be mediated by
shorter fragments. Fig. 2D demonstrates that PB1312 dimers
bind as efficiently to a small C-terminal BTK(PH) fragment
containing only subdomains 5 and 6 as they do to the entire
BTK(PH) domain. No detectable binding to a fragment
containing subdomains 1-4 was seen.
In Vivo Interaction of Btk PH Domain with fty Dimers. The
combined in vitro binding studies strongly support the inter-
action of the Btk PH region with pry dimers as a potential
mediator ofthe effects of stimulation ofheterotrimeric G-pro-
tein-coupled receptors and/or the regulation of a tyrosine
kinase-dependent pathway.
To test if fry subunits can associate with the Btk unique
region in vivo, an indirect assay system was employed. It has
been shown that cells transfected with M2AChR display a
pertussis toxin-sensitive, carbachol-induced hydrolysis of
inositol phospholipids. In this pathway, B3y is dissociated
from the activated G-protein trimer and then activates the
isoform of phospholipase C (30). Activated PLC hydrolyses
inositol phospholipids, releasing IP. The indirect assay sys-
tem is based on the concept that this ligand-induced pathway
requires free fry dimer as the active component. Any coex-
pressed protein that binds to fry would inhibit the accumu-
lation of IP. Fig. 3A shows the structures of the potential
competitor proteins analyzed for their ability to block het-
erotrimeric G protein receptor-mediated IP release.
Fig. 3B shows the level of IP released in COS-7 cells
transfected with the M2AchR upon addition of 100 juM
carbachol. The control cells transfected with a vector ex-
pressing the lacZ protein display a significant level of IP
released. Cells transfected with a plasmid expressing the
complete BTK(PH) domain inhibit carbachol induction by
70-75%, indicating that BTK(PH) binds the free Pydimer and
neutralizes its activity. The inability of BTK(PH) 1-123 to
inhibit the carbachol induction suggests that the N-terminal
region of the BTK(PH) domain cannot bind fry or binds it
very weakly.
Tryptophan is the only amino acid conserved in subdomain
6 of PH in all characterized sequences (14). To examine the
importance of this conserved tryptophan in 8y binding,
BTK(PH)W124G was constructed in which the conserved
tryptophan (Trp-124) was replaced with a glycine. Coexpres-
sion of this mutated protein together with the M2AChR led to
only a 20-25% inhibition of IP release (Fig. 3B). Since this
mutated protein is expressed at a higher level than the
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FIG. 3. Effect of coexpression of Btk N-terminal regions on
M2AChR-mediated PI hydrolysis. (A) PH domain constructs used in
this study. The Btk unique region fragment in BTK(PH) is the same
as that of GST-BTK(PH) in Fig. 2A, while in BTK(PH)W124G the
conserved Trp-124 is mutagenized to glycane. In BTK(PH)1-123,
subdomain 6 is disrupted at aa 123. (B) Carbachol-induced accumu-
lation of [3H]IP in transfected COS-7 cells. COS-7 cells were trans-
fected with M2AChR cDNA (0.1 pg per well) together with one of the
following cDNAs (total of0.8 plg per well): f-galactosidase (indicated
by LZ), BTK(PH), BTK(PH)1-123, and BTK(PH)W124G. The
cDNAs transfected are indicated in each panel. Cells were stimulated
with 100 uM carbachol for 25 min and [3H]IP released was deter-
mined. Transfection, labeling, and analysis of [3H]IP are described
in the text. Basal level values of [3H]IP released were similar and
were in the range of 1200 200 cpm. Data presented are mean values
ofduplicate determinations in a single experiment and each error bar
shows the range of the determinations. Three additional experiments
gave similar results. (C) Immunoblot analysis of the expression ofthe
transfected Btk constructs. Molecular masses are indicated in kDa.
wild-type BTK(PH) (Fig. 3C), the low inhibition is quite
likely due to reduced affinity toward fry.
DISCUSSION
Heterotrimeric G proteins are present in all eukaryotic cells
and control metabolic and developmental functions by
connecting cell surface receptors to various effectors (31).
Receptor activation of a G protein induces a dissociation of
the GTP-bound a subunit from the 183y dimer and results in
the generation of two potential regulatory molecules. The
regulatory roles of fry dimers in several signaling compo-
nents have recently been reported. These include phospho-
lipase C 132 (19, 30, 32) and 133 (33), phospholipase A2 (34),
several G-protein-coupled receptor kinases (17, 18, 20),
cardiac potassium channel (35), adenyl cyclase (36), phos-
phoinositol 3-kinase (37) mitogen-activated protein and
kinase (38). These observations support the involvement of
heterotrimeric G proteins in a broad array of cellular
signaling pathways. Our results suggest a possible connec-
tion of tyrosine kinases like Btk with heterotrimeric G
proteins.
Btk can be activated and tyrosine-phosphorylated upon
cross-linking of cell surface immunoglobulins on B cells (39)
or ofFc_ receptors on mast cells (24). No direct binding ofBtk
to either immunoglobulin or FcERI has been detected. Btk is
generally found in the soluble cell fraction and is not known
to be lipid modified. While the involvement of heterotrimeric
G proteins in B-cell receptor or Fc6 receptor signaling is at
present controversial (40-44), it is possible that 83'y dimers
could recruit Btk to the membrane following receptor acti-
vation.
The C-terminal half of the Btk PH domain plays the major
role in the binding of 13'y. This is consistent with the obser-
vation that the C-terminal half of the PH domain in PARK is
critical for the binding of 13y (20). The C-terminal half of the
PH domain of phospholipase C y, which contains a split PH
domain, is sufficient for 83'y binding in vitro (21). Two recent
reports utilized NMR to define solution structures for the PH
domains of pleckstrin (45) and 13-spectrin (46). Despite the
low amino acid identity among PH domains, these studies
suggest that PH domains may all possess a similar three-
dimensional structure (seven antiparallel 13 sheets and a
C-terminal a-helix), which supports a common function for
many PH domains. The a-helix structure of subdomain 6 is
highly conserved (45, 46). The conservation of specific amino
acids within the analogous regions of P3ARK and Btk is quite
limited (Fig. 1), but the general structure of the exposed
a-helix would be conserved.
The tryptophan in subdomain 6 of the PH domain is unique
in being highly conserved. Peptide fragments of the 1ARK
PH domain containing this residue could competitively in-
hibit the interaction of BARK with 1B3y dimers (20). The
inhibitory effect of the Btk PH domain for frinduced
phospholipase C 83 activation was reduced by replacing this
tryptophan with glycine. Touhara et al. (21) recently reported
that fusion proteins of GST with various PH domains includ-
ing Btk could bind to 1By in vitro. Thus, despite a relatively
weak conservation at the primary sequence level, there
appears to be a common protein-protein interaction for many
PH domains.
One XLA patient is reported to have an insertion of 7 aa
between aa 103 and 104 (9), which disrupts subdomain 5 ofthe
Btk PH domain. The severe XLA phenotype of this patient
(undetectable B cells and immunoglobulin levels) suggests
that this domain is critical for the biological function of Btk.
Phe-102 and Val-104 in subdomain 5 ofthe Btk PH domain are
well conserved in many PH domains and these two residues
are implicated to form a hydrophobic core that stabilized the
three-dimensional structure of the PH domain (46). The 7-aa
insertion between these two residues may destabilize the
structure of the Btk in this XLA patient. It will be interesting
to determine if such insertions have an inhibitory effect on the
binding activity of the Btk PH domain to fry dimers. In XID
mice, the altered residue is located within the N-terminal
region of the PH domain at residue 28 within subdomain 2 (3,
4). The N-terminal portion of the Btk PH domain is not
necessary for fly binding but could determine interactions
with other molecules or regulate the avidity of interaction
with different fry dimers in the cell.
A
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Many proteins involved in diverse functions, including the
,f subunit of G protein, have a repetitive 40-aa sequence
motif, within which several amino acids and their spatial
relationships are highly conserved (WD-40 motif) (31, 47-51).
While fARK most likely binds to fBy of the heterotrimeric G
protein, it cannot be ruled out that other PH domain-
containing proteins may bind different WD-40 proteins.
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